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Allopregnanolone and its equipotent stereoisomer, pregnanolone (together termed ALLO),
are neuroactive steroids that positively and allosterically modulate the action of gamma-
amino-butyric acid (GABA) at GABAA receptors. Levels of ALLO are reduced in the
cerebrospinal ﬂuid of female premenopausal patients with post-traumatic stress disorder
(PTSD), a severe, neuropsychiatric condition that affects millions, yet is without a
consistently effective therapy. This suggests that restoring downregulated brain ALLO
levels in PTSD may be beneﬁcial. ALLO biosynthesis is also decreased in association
with the emergence of PTSD-like behaviors in socially isolated (SI) mice. Similar to PTSD
patients, SI mice also exhibit changes in the frontocortical and hippocampal expression of
GABAA receptor subunits, resulting in resistance to benzodiazepine-mediated sedation
and anxiolysis. ALLO acts at a larger spectrum of GABAA receptor subunits than
benzodiazepines, and increasing corticolimbic ALLO levels in SI mice by injecting ALLO
or stimulating ALLO biosynthesis with a selective brain steroidogenic stimulant, such as
S-norﬂuoxetine, at doses far below those that block serotonin reuptake, reduces PTSD-like
behavior in these mice.This suggests that synthetic analogs of ALLO, such as ganaxolone,
may also improve anxiety, aggression, and other PTSD-like behaviors in the SI mouse
model. Consistent with this hypothesis, ganaxolone (3.75–30 mg/kg, s.c.) injected 60 min
before testing of SI mice, induced a dose-dependent reduction in aggression toward a
same-sex intruder and anxiety-like behavior in an elevated plus maze. The EC50 dose of
ganaxolone used in these tests also normalized exaggerated contextual fear conditioning
and, remarkably, enhanced fear extinction retention in SI mice. At these doses, ganaxolone
failed to change locomotion in an open ﬁeld test. Therefore, unlike benzodiazepines,
ganaxolone at non-sedating concentrations appears to improve dysfunctional emotional
behavior associated with deﬁcits in ALLO in mice and may provide an alternative treatment
for PTSD patients with deﬁcits in the synthesis of ALLO. Selective serotonin reuptake
inhibitors (SSRIs) are the only medications currently approved by the FDA for treatment of
PTSD, although they are ineffective in a substantial proportion of PTSD patients. Hence, an
ALLO analog such as ganaxolone may offer a therapeutic GABAergic alternative to SSRIs
for the treatment of PTSD or other disorders in which ALLO biosynthesis may be impaired.
Keywords: ganaxolone, allopregnanolone, selective brain steroidogenic stimulants, 5α-reductase type I, PTSD,
PTSD therapy, anxiety disorders, GABAA receptor
INTRODUCTION
Traumatic life events involving the threat of injury or death, such as
combat exposure, sexual assault, witnessing of terroristic attacks,
motor vehicle accidents, or involvement in natural disasters may
lead to post-traumatic stress disorder (PTSD). PTSD symptoms
appear following the traumatic event and fail to extinguish or may
worsen over time. PTSD symptoms deﬁned by the Diagnostic
and Statistical Manual of Mental Disorders-5 (DSM-5; Ameri-
can Psychiatric Association, 2013) include intrusive memories of
the event, recurrent ﬂashbacks and nightmares, emotional and
physiological reactions to trauma reminders, difﬁculty sleeping,
trouble concentrating, irritability and aggression, increased star-
tle, hypervigilance, strong negative emotions and beliefs related
to the trauma, emotional numbing and avoidance of reminders
of the event. An estimated 7–8% of Americans will experience
PTSD at some point in their lives, and about 3.6% of U.S. adults
aged 18–54 (5.2 million people) will have PTSD during the course
of a given year. The prevalence of PTSD in women (10.4%) is
about twice that in men (5.0%), representing a relatively small
portion of individuals who have experienced at least one trau-
matic event (60.7% of men and 51.2% of women). However,
exposure to certain types of trauma, such as sexual assault and
combat, is associated with a substantially higher (15–30%) risk
for PTSD. PTSD is also associated with increased rates of other
psychiatric and medical comorbidities including depression, anxi-
ety disorders, traumatic brain injury, chronic pain, cardiovascular
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disorders, metabolic syndrome, and substance abuse, particularly
tobacco and alcohol dependence (Rasmusson et al., 2010; Carlson
et al., 2011; Friedman et al., 2014; Rasmusson and Shalev, 2014;
Scioli-Salter et al., 2014).
Notwithstanding the prevalence of this debilitating psychi-
atric disorder in the general population, the only FDA-approved
drugs for the treatment of PTSD are the selective serotonin reup-
take inhibitors (SSRIs; Brady et al., 2000; Davidson et al., 2001;
Marshall et al., 2001; Tucker et al., 2001). The response rate to
these drugs, however, is relatively small, and some studies have
shown that male combat veterans, in particular, may be resis-
tant to their therapeutic effects, although ethnic differences may
play a role in veteran response rates (Hertzberg et al., 2000; Zohar
et al., 2002; Friedman et al., 2007; Panahi et al., 2011). The search
for neurobiological biomarkers for PTSD is therefore a current
focus of investigation in the hope that a better understanding
of individually variable neurobiological risk factors for PTSD
will spur development of more speciﬁc and individually effective
therapies.
Stress-induced alterations in the composition of GABAA/
benzodiazepine receptor complexes are involved in the lack of
response to classical benzodiazepine ligands as well as in the pro-
duction of dysfunctional behaviors following stress or traumatic
events, as documented in both preclinical and clinical studies. In
postmortem studies, alterations in GABAA receptor binding and
receptor subunit composition, as well as in in GABA synthesis
and transport are associated with anxiety disorders and depres-
sion in humans (Vaiva et al., 2004; Geuze et al., 2008). In studies of
patients with PTSD,GABA levels are reduced (Kugaya et al., 2003),
as are GABAA/benzodiazepine receptor binding (Bremner et al.,
2000). Similarly, in rodents, chronic stress and fear conditioning
have been shown to diminish GABA-mediated neurotransmis-
sion within the amygdala (Martijena et al., 2002), by decreasing
expression of genes for GABA synthesizing enzymes, decreas-
ing NE α1-stimulated GABA release from interneurons within
the basolateral nucleus of the amygdala (BLA; Braga et al., 2004),
downregulating gephyrin, a protein that anchors synaptic GABAA
receptors, and downregulating synaptic GABAA receptors them-
selves (Chhatwal et al., 2005; Heldt and Ressler, 2007). Together,
these studies suggest why benzodiazepines have not been found
to be beneﬁcial in treating the core symptoms of PTSD (Geuze
et al., 2008). In addition, recent work shows that reductions in
GABA synthesis by knockdown of GAD67 in the amygdala, as
well as speciﬁc knockdown of the GABAA receptor α1 subunit
that confers benzodiazepine sensitivity on corticotropin releasing
factor (CRF) neurons, disrupts extinction (Gafford et al., 2012;
Heldt et al., 2012).
Levels of neurosteroids that positively and allosterically mod-
ulate GABA action at GABAA receptors (Puia et al., 1990, 1991;
Belelli and Lambert, 2005) also have been found to be low in PTSD
patients (Rasmusson et al., 2006). In premenopausal women,
cerebrospinal ﬂuid (CSF) levels of ALLO and its equipotent
stereoisomer pregnanolone (together termed ALLO) were 40%
of the levels seen in healthy subjects and were inversely correlated
with PTSD re-experiencing and comorbid depressive symptoms
(Rasmusson et al., 2006). In fact, levels were lowest in those
PTSD patients with current comorbid depression. In addition, the
ratio of ALLO to its steroid precursor, 5α-dihydroprogesterone
(5α-DHP), was decreased among the PTSD patients, suggesting
dysfunction of the enzymes involved in ALLO synthesis (Rasmus-
son et al., 2006). Similarly, among recently deployedmale veterans,
the ratio of ALLO to progesterone, the precursor for 5α-DHP, was
lowest in those veterans with themost severe PTSD and depression
symptoms (Kilts et al., 2010).
Although neurosteroids such as ALLO have activity at all
subtypes of GABAA receptors, they have highest afﬁnity for a
benzodiazepine-resistant subset of extrasynaptic GABAA recep-
tors composed of α4 and δ subunit combinations or α6, γ,
and β subunit combinations (Lambert et al., 2003; Belelli and
Lambert, 2005). These extrasynaptic receptors are activated by
concentrations of GABA lower than that required for activa-
tion of synaptically located GABAA receptors. As a consequence,
extrasynaptic GABAA receptors are thought to maintain a tonic
inhibitory conductance that modulates gain in neuronal output
during periods of increased input (Mitchell and Silver, 2003;
Semyanov et al., 2003, 2004; Mody and Pearce, 2004; Sun et al.,
2004), as occurs during stress. Of note, α4, δ, and α6 GABAA
receptor subunits increase under conditions in which ALLO lev-
els are decreased (Smith et al., 1998; Follesa et al., 2001; Gulinello
et al., 2002; Sundstrom-Poromaa et al., 2002; Pinna et al., 2006b).
In hippocampus (at least, as other areas have not yet been stud-
ied), extrasynaptic GABAA receptors also appear to be reciprocally
upregulated when synaptic GABAA receptors are downregulated.
This suggests that after fear conditioning when synaptic GABAA
receptors are downregulated in the amygdala, maintenance of
adequate GABA tone in the amygdala may depend on positive
modulation of extrasynaptic GABAA receptors by neurosteroids,
such asALLO, that are synthesized and released locally or that enter
the brain after release from the adrenal gland. Thus, pharmacolog-
ical interventions aimed at normalizing brainALLO levels in PTSD
patients with deﬁciencies in ALLO synthesis, might be expected to
restore GABAergic neurotransmission and enhance recovery from
PTSD.
We previously sought to investigate this hypothesis in mice
subjected to four weeks of social isolation, which results in a
70% reduction in ALLO and 5α-DHP biosynthesis (Matsumoto
et al., 1999; Dong et al., 2001). Importantly, the largest decrease of
ALLO induced by social isolation was found in the amygdala and
hippocampus, followed by the olfactory bulb and frontal cortex
(Pibiri et al., 2008). ALLO levels failed to change in the cerebellum
and striatum (Pibiri et al., 2008). In situ immunohistochemi-
cal studies further demonstrated that 5α-reductase conversion
of 5α-DHP to ALLO, the rate-limiting enzymatic step in ALLO
biosynthesis, was speciﬁcally decreased in cortical pyramidal
neurons of layers V–VI, hippocampal CA3 pyramidal neurons,
glutamatergic granular cells of the dentate gyrus, and pyramidal-
like neurons of the basolateral amygdala (Agís-Balboa et al., 2007).
Notably, brain interconnections arising from these corticolimbic
areas play a primary role in the regulation of emotional behav-
ior, including fear responses, as demonstrated by both human
and basic research studies (Myers and Davis, 2007). Accord-
ingly, in SI mice, downregulation of ALLO biosynthesis was
associated with the emergence of neurobehavioral dysfunction
including anxiety-like behavior and aggression towards same-sex
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intruders (Matsumoto et al., 1999; Pinna et al., 2003, 2006a, 2008;
Pibiri et al., 2008). Furthermore, SI mice exposed in a novel
environment (i.e., the context) to the administration of acous-
tic tones preceding unconditioned footshock stimuli, exhibited
exaggerated conditioned contextual fear response and impaired
fear extinction (Pibiri et al., 2008; Pinna et al., 2008). Thus, pro-
tracted social isolation combined with fear-conditioning could
be a suitable mouse model to study emotional behaviors and
neurochemical alterations related to PTSD (Pibiri et al., 2008;
Pinna, 2010).
Similar to PTSD patients, SI mice also show resistance to
classical benzodiazepine ligands such as diazepam and zolpidem
in association with changes in mRNA and protein expression
for several GABAA receptor subunits in the frontal cortex and
hippocampus (Pinna et al., 2006b; Nin Schuler et al., 2011).
Expression of GABAA receptor subunits α1, α2, and γ2 were
reduced by approximately 50%, whereas the mRNAs encoding
α5 and α4 subunits, which confer increased sensitivity to neu-
roactive steroids such as ALLO, were increased by approximately
130% compared to levels in group-housed control mice (Pinna
et al., 2006b). In the SI mice, the systemic administration of ALLO
or infusion of ALLO directly into the basolateral amygdala had
a strong anti-aggressive effect (Nelson and Pinna, 2011). These
results were replicated by the administration of S-norﬂuoxetine at
doses that failed to have serotonergic effects but potently increased
ALLObiosynthesis in target corticolimbic areas, including the hip-
pocampus, basolateral amygdala, and frontal cortex (Pinna et al.,
2006a; Nelson and Pinna, 2011).
The present translational study was undertaken to evalu-
ate whether ganaxolone (3α-hydroxy-3β-methyl-5α-pregnan-20-
one), a 3β-methylated synthetic analog of allopregnanolone
(ALLO) that cannot be converted back into its progesterone pre-
cursors, has a similar capacity to improve anxiety and PTSD-like
behaviors manifested by SI mice, including increased aggression
and exaggerated contextual fear responses. Ganaxolone has shown
efﬁcacy as an anticonvulsant in a number of animal models (e.g.,
Reddy and Rogawski, 2010), and is currently being investigated for
the treatment of refractory epilepsy (Bialer et al., 2013) and PTSD
in human clinical trials1.
MATERIALS AND METHODS
SUBJECTS
Adult male Swiss–Webster mice (Harlan Breeders, Indianapolis),
18–20 g body weight, were maintained under a 12-h dark/light
cycle and provided food and water ad libitum in a vivarium with
temperature and humidity kept near 24◦C and 65%, respectively.
SI mice were housed individually in a 24 × 17 × 12 cm cage
for 3–4 weeks, while group-housed control mice were housed in
groups of 5. Ganaxolone was obtained from Marinus Pharmaceu-
ticals, Inc2. Ganaxolone, pregnanolone, or vehicle (corn oil) in a
volume of 100 μl/10 g was injected subcutaneously (s.c.) 60 min
before behavioral tests of locomotor activity, anxiety-like behav-
ior, and aggressive behavior toward an intruder in the home cage.
In a study of ganaxolone effects on fear extinction and retention,
1http://clinicaltrials.gov
2www.marinuspharma.com
FIGURE 1 | Contextual fear conditioning protocol. Mice were trained in
the conditioning chamber by tone plus footshock, which was repeated
three times every 2 min. The total time in the conditioning chamber was
8 min. To induce retrieval/reactivation of the training memory, mice were
placed in the conditioning chamber for 5 min and immediately after the
reactivation session, they received a single injection of vehicle or
ganaxolone. For the extinction trial (5 days), mice were placed in the
chamber for 5 min without footshock, and freezing was measured as an
indication of contextual fear. After an interval of 7 days (day 12), mice were
reexposed to the chamber without footshock and freezing was measured
as an indicator of the spontaneous reinstatement of contextual fear, or
inversely, as extinction retention.
ganaxolone or vehicle was administered just once, immediately
after the ﬁrst session in which the mice were reexposed to the con-
text in which fear conditioning was performed the day before (i.e.,
subsequent to the ﬁrst reactivation or extinction session; Figure 1).
All experimental protocols were approved by the Ofﬁce of Ani-
mal Care and Institutional Biosafety Committee and the Ofﬁce of
the Vice Chancellor for Research of the University of Illinois at
Chicago.
BEHAVIORAL TESTING
ELEVATED PLUS MAZE
Behavioral testing was performed between 10.00 and 14.00 h in a
light- and sound-controlled room using an elevated plus-shaped
maze constructed of black acrylic and elevated 50 cm above the
ﬂoor (Uz et al., 2004). In this test, mice chose between entering
the two relatively anxiogenic 45 × 10 cm open arms and the two
relatively safe 45 × 10 × 12 cm closed arms that extended from a
10 × 10 cm central platform. Mice were initially placed facing the
closed arm. Entry onto an armwith less than four legs was counted
as a crossing. An arm entry was scored when all four legs were
within the arm. Behavior in the maze was recorded and scored
for 10 min, 60 min after the single s.c., injection of ganaxolone
(3.75–30 mg/kg) or vehicle (corn oil). Time spent on the open
arm and the number of open arm crossings, closed arm crossings,
and closed arm entries were analyzed. After each test, the maze
was wiped with ethanol/water (50% v/v).
RESIDENT–INTRUDER TEST
To test aggression, a male intruder mouse of the same strain as the
resident mouse, was placed in a resident home cage (24 × 17 × 12)
and resident–intruder interactions were videotaped for 10 min.
Aggressive behavior of SI mice was characterized by an initial
pattern of exploratory activity around the intruder, followed by
rearing and tail rattle, accompanied within a few seconds by
wrestling and/or a violent biting attack. The total duration of
wrestling and attack behavior during the 10 min observation
period was measured as previously described (Pinna et al., 2003,
2005), 60 min after administration of a single dose of ganax-
olone (3.75–30 mg/kg, s.c.). To establish whether ganaxolone
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is superior to ALLO in decreasing aggressiveness of SI mice,
an EC50 dose of ganaxolone (10 mg/kg, s.c.) was used in a
comparison experiment with the same dose of pregnanolone
(10 mg/kg, s.c.). Behavioral testing was performed between 10.00
and 14.00 h.
CONTEXTUAL FEAR CONDITIONING
Apparatus
The conditioning and extinction chamber (25 cm wide, 18 cm
high, and 21 cm deep) had a cage ﬂoor made of stainless steel rods
connected to an electric shock generator (San Diego Instrument,
Inc., San Diego, CA). It was surrounded by a frame that emitted
16 infrared photo beams. A computer controlled the delivery of
electric footshocks and recorded beam interruptions and latencies
to beam interruptions (freezing time).
Conditioning trial
The group-housed and SI mice were placed in the chamber and
allowed to explore for 2 min before exposure to a 30 s, 85 DB
acoustic tone (conditioned stimulus, CS) that co-terminated with
a 2 s, 0.5mA electric footshock (unconditioned stimulus, US). The
tone plus footshock was repeated three times randomly within
each subsequent 2 min epoch. One minute after the last tone-
footshock delivery, mice were returned to their home cages. The
total time in the conditioning chamber was 8 min.
Reactivation
Mice were returned to the chamber 24 h later for 5 min with-
out footshock presentation to induce retrieval/reactivation of the
training memory. Immediately after the reactivation session, each
mouse received a single s.c., injection of vehicle or EC50 dose of
ganaxolone (as established in the previous tests of aggression).
Contextual fear
Twenty-four hours after the reactivation/ﬁrst extinction trial, the
mice were placed in the chamber for 5 min without footshock, and
freezing was measured as an indication of contextual fear.
Extinction and extinction retention
Mice were placed in the chamber for the next 5 days in a row start-
ing 24 h after the reactivation session. After a subsequent interval
of 7 days (day 12), mice were reexposed to the chamber without
footshock and freezing was measured as an indicator of the spon-
taneous reinstatement of contextual fear, or inversely as extinction
retention (Figure 1). Freezing was deﬁned as the absence of move-
ment except respiration while the mice remained in a crouched
posture (Pibiri et al., 2008).
MEASUREMENT OF EXPLORATORY ACTIVITY IN A NOVEL CAGE
A computerized AccuScan 12 Animal Activity Monitoring Sys-
tem (Columbus Instruments, Columbus, OH, USA) assisted by
VERSAMAX software (AccuScan Instruments, Columbus, OH,
USA) was used to quantify locomotor activity (Pinna et al., 1997,
2006b). Each activity cage consisted of a 20 × 20 × 20 cm Per-
spex box surrounded by horizontal and vertical infrared sensor
beams. Horizontal sensors beam interruptions were taken as a
measure of horizontal activity, whereas vertical sensor beam inter-
ruptions counted as rearing activity. Activity was recorded from
group-housed and SI mice between 13.00 and 15.00 h for 15 min
beginning 60min after a single injection of vehicle or various doses
of ganaxolone (3.75–30 mg/kg, s.c.).
STATISTICAL ANALYSES
Results are presented as means ± SEMs unless otherwise indi-
cated. Comparisons between the control group and each of
the treatment groups were performed using one-way ANOVA
followed by LSD’s test or repeated measures ANOVA followed
by a Greenhouse–Geisser correction. Signiﬁcance was set at
P < 0.05. Ganaxolone EC50 values were calculated from dose–
response curves analyzed by the “quantal dose–response: probits
test” using the computer program of Tallarida and Murray
equippedwith a statistical package. Statistical comparisons among
the different EC50s were performed with the “cohort package
software3.”
RESULTS
DOSE-DEPENDENT GANAXOLONE EFFECTS ON AGGRESSIVE BEHAVIOR
IN SI MICE
Administration of ganaxolone (3.75–30 mg/kg, s.c.) resulted in
a dose-dependent decrease of aggressive behavior directed by SI
resident mice toward same-sex intruders (Figure 2). There was a
highly signiﬁcant main effect of ganaxolone treatment on aggres-
sive behavior (F4,36 = 6.89, P < 0.001). The dose of 30 mg/kg was
not more efﬁcacious than the 15 mg/kg dose in decreasing aggres-
sion. Equimolar doses of ganaxolone and pregnanolone were
equipotent in ameliorating the social isolation-induced aggres-
sion. The analyses of the dose–response curve resulted in an
EC50 of 9.7 mg/kg of ganaxolone, which was the dose used
in the evaluation of the contextual fear conditioning response
experiments.
ANXIETY-LIKE BEHAVIOR IN GROUP-HOUSED AND SI MICE TREATED
WITH GANAXOLONE
This study conﬁrmed ﬁndings of previous experiments demon-
strating increased anxiety-like behavior in a plus maze in SI
mice compared with group-housed mice (Pinna et al., 2006a;
Nin Schuler et al., 2011). There was a signiﬁcant main effect
of ganaxolone treatment within SI mice and a dose-dependent
effect of ganaxolone treatment on several anxiety-like measures
(ratio of open to closed arm total time: F4,41 = 2.80, P = 0.038;
ratio of open to closed arm rest time F4,41 = 2.66, P = 0.04;
Figures 3 and 4). The lowest dose of ganaxolone (3.75 mg/kg)
only showed a trend towards improvement of anxiety-like behav-
ior expressed as the ratio of open arm to closed arm total time
(P = 0.08; Figure 3). Ganaxolone treatment at the 7.5 mg/kg
dose signiﬁcantly increased the ratios of open arm to closed arm
rest time as well as total time spent in the open arms (P = 0.02
and P = 0.01, respectively). The most effective 15 mg/kg dose of
ganaxolone induced anxiolytic effects as determined by the ratios
of open arm to closed arm rest time and total time (P = 0.007
for both measures). The dose of 30 mg/kg did not elicit an
improvement of social isolation-induced anxiety-like behavior
(Figures 3 and 4).
3www.cohort.com
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FIGURE 2 | Ganaxolone dose-dependently decreases social
isolation-induced aggression of resident mice toward a same-sex
intruder. Dose–response curve resulted in an EC50 dose of 10 mg/kg of
ganaxolone. Equimolar doses of ganaxolone and the GABAA receptor
active, ALLO isoform, pregnanolone were equipotent in decreasing
aggressive behavior in SI mice. Data represent the mean ± SEM of 8–10 SI
mice. *P < 0.01; **P < 0.001, when compared with vehicle-treated (0)
mice.
In group-housed mice, there was a signiﬁcant main effect of
ganaxolone treatment (ratio of open to closed arm total time:
F2,22 = 4.46, P = 0.027). Ganaxolone at a dose of 15 mg/kg,
s.c., did not affect anxiety-like measures. The highest 30 mg/kg
ganaxolone dose did, however, induce an anxiolytic effect as mice
treated with this dose showed an increase in the ratio of open arm
to closed arm total time (P = 0.04; Figure 3) and in the ratio of
open arm to closed arm distance traveled (P = 0.027; not shown).
CONTEXTUAL FEAR RESPONSES IN SI MICE THAT RECEIVED AN EC50
DOSE OF GANAXOLONE
SI mice compared to group-housed mice exposed to contex-
tual fear conditioning exhibited increased freezing and reduced
extinction over a period of ﬁve extinction trials (Figure 5).
Repeated-measures ANOVA with a Greenhouse–Geisser correc-
tion showed a signiﬁcant group by drug treatment by extinction
session interaction for freezing across extinction sessions day 1–
3, the time interval over which extinction continued to decline
(F1.995,43.885 = 3.618; P < 0.035). Post hoc testing revealed that
ganaxolone treatment compared to vehicle treatment resulted in
less freezing in the SI mice. Ganaxolone did not affect freezing
time in the group-housed mice. Importantly, the single EC50 dose
(10 mg/kg) of ganaxolone administered after the ﬁrst fear reacti-
vation/extinction session prevented the spontaneous reemergence
of contextual fear responses after the passage of time—or from
another perspective, enhanced extinction retention (T1,23 = 5.809,
P = 0.025; Figure 5).
EFFECTS OF GANAXOLONE ON EXPLORATORY ACTIVITY IN SI AND
GROUP-HOUSED MICE
Ganaxolone did not reduce exploratory activity in either SI or
group-housed mice, even at the highest dose (30 mg/kg) tested.
FIGURE 3 |The effects of ganaxolone on anxiety-like behavior in SI
mice (red circles) results in a bell shaped dose–response curve, which
is shifted to the right in group-housed mice (black circles). Ganaxolone
in the dose range of 3.75–30 mg/kg improves anxiety-like behavior of SI
mice exposed to an elevated plus maze and assessed by open to close arm
total time, and improved anxiety-like behavior of group-housed mice at the
high dose of 30 mg/kg, s.c. Data represent the mean ± SEM of eight to
fourteen mice. *P < 0.05; **P < 0.01 when compared with vehicle-treated
(0) mice.
There was a trend for the lowest doses of ganaxolone (3.75 and
7.5 mg/kg) to stimulate both horizontal and vertical locomotor
activity in SI mice (Figures 6 and 7).
DISCUSSION
This study assessed the effects of a synthetic ALLO analog, the
neuroactive steroid ganaxolone, on anxiety-like behavior, aggres-
sion, and contextual fear conditioning and extinction, as well as
locomotor activity in male mice. Importantly, ganaxolone admin-
istered s.c. at 3.75–30 mg/kg did not impair exploratory activity
as assessed by characterization of horizontal and vertical locomo-
tion patterns. Ganaxolone did, however, show a strong anxiolytic
effect in mice tested in the elevated plus maze, with lower doses
effective in SI mice with deﬁcits in ALLO, and higher doses effec-
tive in group-housed mice with normal ALLO levels. Ganaxolone
also dose-dependently decreased aggression in SI mice to a same-
sex intruder at doses comparable to ALLO doses with comparable
effects. Most intriguingly, an EC50 dose (10 mg/kg, s.c.) of ganax-
olone, given immediately after reactivation of contextual fear 1 day
after fear conditioning, substantially diminished contextual fear on
subsequent test days in SI mice. In addition, it blocked the spon-
taneous reemergence of contextual fear a week after extinction
was complete – or from another perspective, corrected deﬁcits in
extinction retention exhibited by SI mice. Of note, such deﬁcits
in extinction retention have been observed in studies of PTSD in
humans (e.g.,Milad et al.,2008), thus reinforcing the idea that deﬁ-
ciencies inGABAergic neurotransmission associatedwithdeﬁcient
ALLO biosynthesis constitute a vulnerability to the development
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FIGURE 4 | Ganaxolone dose-dependently decreases social
isolation-induced anxiety-like behavior of mice exposed to an elevated
plus maze, determined by the ratios of open arm to closed arm rest
time. Data represent the mean ± SEM of 8–14 mice. *P < 0.05;
**P < 0.01 when compared with vehicle-treated (0) mice.
FIGURE 5 | Ganaxolone facilitates fear extinction and blocks contextual
fear reconsolidation. SI mice (empty circles) exhibit increased freezing
and reduced extinction compared to group-housed mice over a period of
ﬁve extinction trials. Ganaxolone treatment administered immediately after
a reactivation session (black arrow) compared to vehicle treatment resulted
in less freezing in the SI mice (red circles). Ganaxolone did not affect
freezing time in the group-housed mice (black triangle). Importantly,
ganaxolone prevented the spontaneous reemergence of contextual fear
responses after the passage of time – or from another perspective,
enhanced extinction retention in SI mice. Data represent the mean ± SEM
of 10–12 mice. *P = 0.035 when compared to SI + Ganaxolone;
†P = 0.025 when compared to SI + ganaxolone on recall (day 12).
of PTSD-like behaviors in response to threat, modeled in this
study by exposure to footshock in a Pavlovian fear conditioning
paradigm.
These data are in agreement with previous reports demon-
strating strong anxiolytic effects of ganaxolone at 10 mg/kg i.p. in
rats (Kudagi et al., 2012) and wild-type or GABAA receptor delta
FIGURE 6 | Ganaxolone did not alter exploratory activity determined
as means of horizontal and vertical activity in SI mice even at the
highest dose (30 mg/kg) tested.The lowest doses of ganaxolone (3.75
and 7.5 mg/kg, s.c.) exhibit a trend to increase both horizontal and vertical
locomotor activity in SI mice. Data represent the mean ± SEM of six to
eight SI mice.
FIGURE 7 | Ganaxolone fails to change locomotor measures assessed
as horizontal and vertical activity in group-housed mice. Data
represent the mean ± SEM of six group-housed mice.
subunit knockout mice (Mihalek et al., 1999). These results thus
suggest that ganaxolonemay be useful in clinical practice for a sub-
population of patients in whom anxiety or PTSD symptoms are
related to deﬁcient ALLO biosynthesis. It is possible that ganax-
olone also may ﬁnd application in other disorders characterized
by a downregulation of brain ALLO levels, including depression
(Uzunova et al., 1998; Agis-Balboa et al., 2014).
CURRENT PTSD TREATMENT OPTIONS
Currently, there is no speciﬁc pharmacological treatment for
PTSD. The only FDA approved medications for the management
of this debilitating disorder are the serotonin selective reuptake
inhibitors (SSRIs), paroxetine and sertraline. Although SSRIs
improve symptoms of PTSD in some patients, meta-analyses
have demonstrated that response rates rarely exceed 60% and
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that only 20–30% of patients achieve a full remission of symp-
toms (Westenberg, 1996; Walderhaug et al., 2010; Ipser and
Stein, 2012). Venlafaxine, a serotonin–norepinephrine reuptake
inhibitor (SNRI) was shown to induce a positive clinical response
in 78% of PTSD patients (Davidson et al., 2006). However, only
40% of patients who completed the treatment achieved PTSD
remission and the drug was not effective for PTSD hyperarousal
symptoms (Davidson et al., 2006).
The ﬁnding that low non-serotonergic doses of ﬂuoxetine and
congeners increase ALLO levels as their primary mechanism of
action, suggests that SSRIs acting as selective brain steroidogenic
stimulants (SBSSs; Pinna et al., 2003, 2006a; Pinna, 2014) may
thereby improve psychiatric symptoms and be of use in PTSD
(reviewed in Pinna and Rasmusson, 2012). However, the high
rate of resistance to current medications of this class suggests that
deﬁcits in the activity of enzymes involved in ALLO synthesis
may not be amenable to correction by SSRIs in PTSD—and/or
that the pathophysiology of PTSD is more complex and/or varies
among individuals. The study by Rasmusson et al. (2006), sug-
gested that 3α-hydroxysteroid dehydrogenase (3α-HSD) activity
is downregulated in premenopausal women with PTSD. Work
by Gillespie et al. (2013), on the other hand, showed that a
polymorphism of the 5α-reductase type I gene predicted an
increase in the risk for PTSD in men. This suggests the possi-
bility that the speciﬁc enzyme site responsible for ALLO deﬁciency
in PTSD may differ between men and women, as supported
by the work of Pinna et al. (2008) showing that social isola-
tion downregulates corticolimbic ALLO levels in male rodents
at 5α-reductase, but not female rodents, unless the females are
oophorectomized and replaced with testosterone (Pinna et al.,
2005). Hence, it is possible that SSRIs and SNRIs currently in use
for the treatment of PTSD do not adequately enhance gene expres-
sion or enzymatic function at these sites in individuals resistant to
their therapeutic effects. Therefore, an alternative strategy might
be to directly activate GABAA receptors with an ALLO analog
such as ganaxolone (Gulinello et al., 2003; Kaminski et al., 2004;
Pinna, 2014).
OTHER NEUROSTEROIDOGENIC DRUGS FOR THE POTENTIAL
TREATMENT OF PTSD-LIKE SYMPTOMS
There are several other neurosteroidogenic biomarkers with the
potential to serve as targets for the next generation of anxiolytic,
antidepressant, or PTSD relevant drugs. One of the best stud-
ied is the 18 kDa translocase protein (TSPO; Papadopoulos et al.,
2006; Rupprecht et al., 2009, 2010; Schüle et al., 2011, 2014), for-
mally known as the peripheral benzodiazepine receptor (Costa and
Guidotti, 1991; Costa et al., 1994). TSPO regulates the availability
of neurosteroids in the brain by facilitating access of cholesterol
to the inner mitochondrial membrane and its subsequent conver-
sion to pregnenolone by the rate-limiting step enzyme, P450scc,
locatedwithin the innermitochondrialmembrane (Papadopoulos
et al., 2006; Rupprecht et al., 2009, 2010). TSPO agents have been
shown to potently increase ALLO levels in brain regions that regu-
late emotional behavior, such as the hippocampus and cortex, and
to induce anxiolytic effects (Kita et al., 2004). Several TSPO ligands
have recently been shown to be effective in rodentmodels of PTSD,
including AC-5216/XBD173 and YL-IPA08 (Qiu et al., 2013).
Another neurosteroidogenic target is the pregnane xenobiotic
receptor (PXR), awell-characterized, ubiquitous and promiscuous
nuclear receptor important for metabolism and xenobiotic clear-
ance in liver, kidney and intestine (Geick et al., 2001; Dussault and
Forman, 2002; Francis et al., 2002; Kliewer et al., 2002). The recent
discovery of PXR expression in brain has suggested a potential
role for PXR in neural plasticity, as well. For example, PXR gene
expression ﬂuctuates across the estrous cycle in female rats and
increases in the midbrain following mating, while knockdown
of PXR expression in the ventral–tegmental area (VTA) reduces
biosynthesis of ALLO in response to mating (reviewed in Frye,
2011; Frye et al., 2012, 2013). Inhibition of TSPO with the selec-
tive antagonist, PK11195, also reduces ALLO levels in midbrain,
and reduces lordosis, effects reversed by ALLO administration.
Together these data suggest that PXR may be upstream of TSPO
(Frye et al., 2014).
The endocannabinoid system also has attracted attention as a
steroidogenic target. The primary active ingredient of Cannabis
sativa, Δ9-tetrahydrocannabinol (THC), increases pregnenolone
synthesis in brain via activation of the type 1 cannabinoid recep-
tor (CB1; Vallée et al., 2014). Other cannabinoid ligands thus are
being studied for their potential as anxiety and PTSD therapies.
There are interesting similarities between the cannabinoid system
and ALLO in the regulation of emotion. Levels of ALLO and the
endocannabinoid, anandamide (AEA) are decreased in models of
stress-induced anxiety and depression (Matsumoto et al., 1999;
Dong et al., 2001; Pibiri et al., 2008; Rademacher et al., 2008; Hill
et al., 2009), and bothALLO and drugs that increase ALLO orAEA
levels have similar effects on fear responses (Costanzi et al., 2003;
Pibiri et al., 2008; Pinna et al., 2008; Lin et al., 2009).
The potential role of the endocannabinoid system in regulating
emotional experience is further supported by the density of endo-
cannabinoid receptors on glutamatergic neurons in emotion rele-
vant areas such as the amygdala, hippocampus, and cortex (Slanina
and Schweitzer, 2005; Katona, 2009). In addition, cannabinoids
regulate intracellular peroxisome proliferator-activated receptors
(PPARs), members of the nuclear hormone receptorsuperfamily
(Forman et al., 1996; O’Sullivan, 2007; Pistis and Melis, 2010).
The endocannabinoids, AEA and palmitoylethanolamide (PEA)
are PPAR-α agonists, and PEA’s action at PPAR-α induces anal-
gesia by enhancing ALLO biosynthesis (Sasso et al., 2012). A
PEA-related increase in brain stem ALLO levels also poten-
tiates pentobarbital hypnosis, an effect mimicked by PPAR-α
agonists and prevented by ALLO biosynthetic enzyme block-
ers (Sasso et al., 2010, 2012). Also of note, PEA administration
shows antidepressant effects equal to those of ﬂuoxetine (Umathe
et al., 2011; Yu et al., 2011) that activate ALLO biosynthesis
(Pinna et al., 2003, 2006a).
The ﬁnding that activation of CB1 and PPAR-α receptors is
capable of inducing ALLO biosynthesis, together with the piv-
otal role of ALLO in facilitating the action of GABA at GABAA
receptors, invites speculation about whether cannabinoid-related
anxiolytic and anti-fear effects are due to the induction of
corticolimbic ALLO biosynthesis. Cannabidiol, a non-sedating
phytocannabinoid with a remarkably safe proﬁle in humans, as
well as other cannabinoids (Lin et al., 2006; Kobilo et al., 2007;
Suzuki et al., 2008; Stern et al., 2012) have recently been shown
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to disrupt recent and older contextual fear memories by interfer-
ing with their reconsolidation. This effect of cannabidiol is long
lasting and can be prevented by pharmacological antagonism of
CB1 receptors (Stern et al., 2012). Interestingly then, the anti-fear
effects of cannabidiol resulting in reconsolidation blockade were
similar to the effects of midazolam, which like ALLO, activates
GABAA receptors (Stern et al., 2012).
The ﬁndings of the current study also support a role for
GABAA receptors in reconsolidation blockade and recovery from
conditioned fear (Duvarci and Nader, 2004; Bustos et al., 2006).
Administration of the ALLO-like compound, ganaxolone, during
a critical time-limited window following exposure to conditioned
contextual cues (Stern et al., 2012), markedly reduced the expres-
sion of fear in subsequent extinction trials and prevented the spon-
taneous recovery of fear (Figure 5). Given that PTSD is associated
with benzodiazepine resistance, synaptic GABAA/benzodiazepine
receptor complexes in humans with PTSD are decreased, and
synaptic GABAA receptors in the amygdala decrease after fear
conditioning in rodents (Mou et al., 2011), it is tempting to specu-
late that blockade of reconsolidation may result from activation of
extrasynaptic receptors,which are highly sensitive to neurosteroids
(Belelli and Lambert, 2005). Furthermore, given that synaptic
GABAA receptors in the amygdala are restored after extinction
of fear in rodents (Heldt and Ressler, 2007), it is possible that such
restoration is a functional consequence of activation of extrasy-
naptic GABAA receptors by GABAergic neurosteroids such as
ALLO during extinction.
CONCLUSION
Post-traumatic stress disorder appears to be a multifactorial dis-
order with several symptom clusters and involving neurochemical
deﬁcits that may vary among individuals with PTSD. Current
treatments for PTSD are only efﬁcacious in some patients or in
some symptom clusters and not in others. Accumulated knowl-
edge about the heterogeneous pathophysiology of PTSD thus
suggests that treatments of the future should be “individually
designed” rather than one-size ﬁts all. In the case of PTSD patients
who exhibit deﬁcient ALLO biosynthesis and related deﬁcits in
GABAergic neurotransmission, ganaxolone administration may
facilitate recovery. Perhaps then, future clinical trials of ganax-
olone should be guided by pre-treatment ascertainment of ALLO
levels and other relevant GABAergic systembiomarkers as possible
predictors of treatment efﬁcacy.
ACKNOWLEDGMENTS
The work was supported by National Institute of Mental Health
Grant MH 085999 and Marinus Pharmaceuticals, Inc., funding to
Graziano Pinna.
REFERENCES
Agis-Balboa, R. C., Guidotti, A., and Pinna, G. (2014). 5α-reductase type I expres-
sion is downregulated in the prefrontal cortex/Brodmann’s area 9 (BA9) of
depressed patients. Psychopharmacology (Berl.) doi: 10.1007/s00213-014-3567-5
[Epub ahead of print].
Agís-Balboa, R. C., Pinna, G., Pibiri, F., Kadriu, B., Costa, E., and Guidotti, A.
(2007). Down-regulation of neurosteroid biosynthesis in corticolimbic circuits
mediates social isolation-induced behavior in mice. Proc. Natl. Acad. Sci. U.S.A.
104, 18736–18741. doi: 10.1073/pnas.0709419104
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of
Mental Disorders, 5th Edn. Arlington, VA: American Psychiatric Publishing.
Belelli, D., and Lambert, J. J. (2005). Neurosteroids: endogenous regulators of the
GABAA receptor. Nat. Rev. Neurosci. 6, 565–575. doi: 10.1038/nrn1703
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., and
White, H. S. (2013). Progress report on new antiepileptic drugs: a summary
of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res. 103, 2–30. doi:
10.1016/j.eplepsyres.2012.10.001
Brady, K., Pearlstein, T.,Asnis, G.M., Baker,D., Rothbaum, B., Sikes, C., et al. (2000).
Efﬁcacy and safety of sertraline treatment of posttraumatic stress disorder. JAMA
283, 1837–1844. doi: 10.1001/jama.283.14.1837
Braga, M. F., Aroniadou-Anderjaska, V., Manion, S. T., Hough, C. J., and
Li, H. (2004). Stress impairs alpha(1A) adrenoceptor-mediated noradrenergic
facilitation of GABAergic transmission in the basolateral amygdala. Neuropsy-
chopharmacology 29, 45–58. doi: 10.1038/sj.npp.1300297
Bremner, J. D., Innis, R. B., Southwick, S. M., Staib, L., Zoghbi, S., and Charney,
D. S. (2000). Decreased benzodiazepine receptor binding in prefrontal cortex in
combat-related posttraumatic stress disorder. Am. J. Psychiatry 157, 1120–1126.
doi: 10.1176/appi.ajp.157.7.1120
Bustos, S. G., Maldonado, H., and Molina, V. A. (2006). Midazolam
disrupts fear memory reconsolidation. Neuroscience 139, 831–842. doi:
10.1016/j.neuroscience.2005.12.064
Carlson, K. F., Kehle, S. M., Meis, L. A., Greer, N., Macdonald, R., Rutks, I., et al.
(2011). Prevalence, assessment, and treatment of mild traumatic brain injury and
posttraumatic stress disorder: a systematic review of the evidence. J. HeadTrauma
Rehabil. 26, 103–115. doi: 10.1097/HTR.0b013e3181e50ef1
Chhatwal, J. P., Myers, K. M., Ressler, K. J., and Davis, M. (2005). Regulation of
gephyrin and GABAA receptor binding within the amygdala after fear acquisi-
tion and extinction. J. Neurosci. 25, 502–506. doi: 10.1523/JNEUROSCI.3301-
04.2005
Costa, E., Auta, J., Guidotti, A., Korneyev, A., and Romeo, E. (1994). The pharma-
cology of neurosteroidogenesis. J. Steroid Biochem. Mol. Biol. 49, 385–389. doi:
10.1016/0960-0760(94)90284-4
Costa, E., and Guidotti A. (1991). Diazepam binding inhibitor (DBI): a peptide
with multiple biological actions. Life Sci. 49, 325–344. doi: 10.1016/0024-
3205(91)90440-M
Costanzi, M., Battaglia, M., Populin, R., Cestari, V., and Castellano, C. (2003).
Anandamide and memory in CD1 mice: effects of immobilization stress and
of prior experience. Neurobiol. Learn. Mem. 79, 204–211. doi: 10.1016/S1074-
7427(03)00006-6
Davidson, J., Baldwin, D., Stein, D. J., Kuper, E., Benattia, I., Ahmed, S., et al. (2006).
Treatment of posttraumatic stress disorder with venlafaxine extended release: a
6-month randomized controlled trial. Arch. Gen. Psychiatry 63 , 1158–1165. doi:
10.1001/archpsyc.63.10.1158
Davidson, J. R. T., Rothbaum, B. O., van der Kolk, B. A., Sikes, C. R., and Farfel,
G. M. (2001). Multicenter, double-blind comparison of sertraline and placebo in
the treatment of posttraumatic stress disorder. Arch. Gen. Psychiatry 58, 485–492.
doi: 10.1001/archpsyc.58.5.485
Dong, E., Matsumoto, K., Uzunova,V., Sugaya, I., Costa, E., and Guidotti, A. (2001).
Brain 5alpha-dihydroprogesterone and allopregnanolone synthesis in a mouse
model of protracted social isolation. Proc. Natl. Acad. Sci. U.S.A. 98, 2849–2854.
doi: 10.1073/pnas.051628598
Dussault, I., and Forman, B. M. (2002). The nuclear receptor PXR: a master reg-
ulator of “homeland” defense. Crit. Rev. Eukaryot. Gene Expr. 12, 53–64. doi:
10.1615/CritRevEukaryotGeneExpr.v12.i1.30
Duvarci, S., and Nader, K. (2004). Characterization of fear memory reconsolidation.
J. Neurosci. 24 , 9269–9275. doi: 10.1523/JNEUROSCI.2971-04.2004
Follesa, P., Cagetti, E., Mancuso, L., Biggio, F., Manca, A., Maciocco, E., et al. (2001).
Increase in expression of the GABA(A) receptor alpha(4) subunit gene induced
by withdrawal of, but not by long-term treatment with, benzodiazepine full or
partial agonists. Brain Res. Mol. Brain Res. 92, 138–148. doi: 10.1016/S0169-
328X(01)00164-4
Forman, B. M., Chen, J., and Evans, R. M. (1996). The peroxisome proliferator-
activated receptors: ligands and activators. Ann. N. Y. Acad. Sci. 804, 266–275.
doi: 10.1111/j.1749-6632.1996.tb18621.x
Francis, G. A., Fayard, E., Picard, F., and Auwerx, J. (2002). Nuclear recep-
tors and the control of metabolism. Annu. Rev. Physiol. 65, 261–311. doi:
10.1146/annurev.physiol.65.092101.142528
Frontiers in Cellular Neuroscience www.frontiersin.org September 2014 | Volume 8 | Article 256 | 8
Pinna and Rasmusson Ganaxolone blocks contextual fear reconsolidation
Friedman, M. J., Keane T. M., Resick, P. A. (eds). (2014). Handbook of PTSD, 2nd
Edn. New York, NY: Guilford Publications, Inc.
Friedman, M. J., Marmar, C. R., Baker, D. G., Sikes, C. R., and Farfel, G. M.
(2007). Randomized, double-blind comparison of sertraline and placebo for
posttraumatic stress disorder in a Department of Veterans Affairs setting. J. Clin.
Psychiatry 68, 711–720. doi: 10.4088/JCP.v68n0508
Frye, C. A. (2011). Novel substrates for, and sources of, progestogens for
reproduction. J. Neuroendocrinol. 23, 961–973. doi: 10.1111/j.1365-2826.2011.
02180.x
Frye, C. A., Koonce, C. J., and Walf, A. A. (2014). The pregnane xenobiotic receptor,
a prominent liver factor, has actions in the midbrain for neurosteroid synthesis
and behavioral/neural plasticity of female rats. Front. Syst. Neurosci. 8:60. doi:
10.3389/fnsys.2014.00060
Frye, C. A., Koonce, C. J., Walf, A. A., and Rusconi, J. C. (2013). Motivated
behaviors and levels of 3α,5α-THP in the midbrain are attenuated by knock-
ing down expression of pregnane xenobiotic receptor in the midbrain ventral
tegmental area of proestrous rats. J. Sex. Med. 10, 1692–1706. doi: 10.1111/
jsm.12173
Frye, C. A., Paris, J. J., Walf, A. A., and Rusconi, J. C. (2012). Effects and mecha-
nisms of 3α,5α,-THP on emotion, motivation, and reward functions involving
pregnane xenobiotic receptor. Front. Neurosci. 5:136. doi: 10.3389/fnins.2011.
00136
Gafford,G.M., Guo, J. D., Flandreau, E. I., Hazra, R., Rainnie,D. G., andRessler, K. J.
(2012). Cell-type speciﬁc deletion of GABA(A)alpha1 in corticotropin-releasing
factor-containing neurons enhances anxiety and disrupts fear extinction. Proc.
Natl. Acad. Sci. U.S.A. 109, 16330–16335. doi: 10.1073/pnas.1119261109
Geick, A., Eichelbaum,M., and Burk, O. (2001). Nuclear receptor response elements
mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276, 14581–
14587. doi: 10.1074/jbc.M010173200
Geuze, E., van Berckel, B. N., Lammertsma, A. A., Boellaard, R., de Kloet, C. S.,
Vermetten, E., et al. (2008). Reduced GABAA benzodiazepine receptor binding
in veterans with post-traumatic stress disorder. Mol. Psychiatry 13, 74–83. doi:
10.1038/sj.mp.4002054
Gillespie, C. F., Almli, L. M., Smith, A. K., Bradley, B., Kerley, K., Crain, D.
F., et al. (2013). Sex dependent inﬂuence of a functional polymorphism in
steroid 5-alpha-reductase type 2 (SRD5A2) on post-traumatic stress symptoms.
Am. J. Med. Genet. B Neuropsychiatr. Genet. 162, 283–292. doi: 10.1002/ajmg.
b.32147
Gulinello, M., Gong, Q. H., and Smith, S. S. (2002). Progesterone with-
drawal increases the alpha4 subunit of the GABA(A) receptor in male rats
in association with anxiety and altered pharmacology: a comparison with
female rats. Neuropharmacology 43, 701–714. doi: 10.1016/S0028-3908(02)
00171-5
Gulinello, M., Gong, Q. H., and Smith, S. S. (2003). Progesterone withdrawal
increases the anxiolytic actions of gaboxadol: role of alpha4betadelta GABA(A)
receptors. Neuroreport 14, 43–46. doi: 10.1097/00001756-200301200-00008
Heldt, S. A., Mou, L., and Ressler, K. J. (2012). In vivo knockdown of GAD67 in
the amygdala disrupts fear extinction and the anxiolytic-like effect of diazepam
in mice. Transl. Psychiatry 2, e181. doi: 10.1038/tp.2012.101
Heldt, S. A., and Ressler, K. J. (2007). Training-induced changes in the expres-
sion of GABAA-associated genes in the amygdala after the acquisition and
extinction of Pavlovian fear. Eur. J. Neurosci. 26, 3631–3644. doi: 10.1111/j.1460-
9568.2007.05970.x
Hertzberg, M. A., Feldman, M. E., Beckham, J. C., Kudler, H. S., and
Davidson, J. R. (2000). Lack of efﬁcacy for ﬂuoxetine in PTSD: a placebo
controlled trial in combat veterans. Ann. Clin. Psychiatry 12, 101–105. doi:
10.3109/10401230009147096
Hill, M. N., Miller, G. E., Carrier, E. J., Gorzalka, B. B., and Hillard, C. J.
(2009). Circulating endocannabinoids and N-acyl ethanolamines are differen-
tially regulated in major depression and following exposure to social stress.
Psychoneuroendocrinology 34, 1257–1262. doi: 10.1016/j.psyneuen.2009.03.013
Ipser, J. C., and Stein, D. J. (2012). Evidence-based pharmacotherapy of post-
traumatic stress disorder (PTSD). Int. J. Neuropsychopharmacol. 15, 825–840.
doi: 10.1017/S1461145711001209
Kaminski, R. M., Livingood, M. R., and Rogawski, M. A. (2004). Allopregnanolone
analogs that positively modulate GABA receptors protect against partial seizures
induced by 6-Hz electrical stimulation in mice. Epilepsia 45, 864–867. doi:
10.1111/j.0013-9580.2004.04504.x
Katona, I. (2009). Endocannabinoid receptors: CNS localization of the CB1
cannabinoid receptor. Curr. Top. Behav. Neurosci. 1, 65–86. doi: 10.1007/978-
3-540-88955-7_3
Kilts, J. D., Tupler, L. A., Keefe, F. J., Payne, V. M., Hamer, R. M., Naylor, J. C., et al.
(2010). Neurosteroids and self-reported pain in veterans who served in the U.S.
Military after September 11, 2001. Pain Med. 11, 1469–1476. doi: 10.1111/j.1526-
4637.2010.00927.x
Kita, A., Kohayakawa, H., Kinoshita, T., Ochi, Y., Nakamichi, K., Kurumiya, S.,
et al. (2004). Antianxiety and antidepressant-like effects of AC-5216, a novel
mitochondrial benzodiazepine receptor ligand. Br. J. Pharmacol. 142, 1059–1072.
doi: 10.1038/sj.bjp.0705681
Kobilo, T.,Hazvi, S., andDudai,Y. (2007). Role of cortical cannabinoidCB1 receptor
in conditioned taste aversion memory. Eur. J. Neurosci. 25, 3417–3421. doi:
10.1111/j.1460-9568.2007.05561.x
Kliewer, S. A., Goodwin, B., and Willson, T. M. (2002). The nuclear pregnane X
receptor: a key regulator of xenobiotic metabolism. Endocr. Rev. 23, 687–702. doi:
10.1210/er.2001-0038
Kudagi, B. L., Pravin, R., Kumar, S. K., and Basha, S. (2012). Evaluation of
anti-anxiety, sedative and motor co-ordination properties of ganaxolone in
comparison with diazepam in rodent models IOSR. J. Dental Med. Sci. 1, 42–47.
Kugaya, A., Sanacora, G., Verhoeff, N. P., Fujita, M., Mason, G. F., Seneca, N. M.,
et al. (2003). Cerebral benzodiazepine receptors in depressed patients measured
with [123I]iomazenil SPECT. Biol. Psychiatry 54, 792–799. doi: 10.1016/S0006-
3223(02)01788-2
Lin, H. C., Mao, S. C., and Gean, P. W. (2006). Effects of intra-amygdala infusion of
CB1 receptor agonists on the reconsolidation of fear-potentiated startle. Learn.
Mem. 13, 316–321. doi: 10.1101/lm.217006
Lin, H. C., Mao, S. C., Su, C. L., and Gean, P.W. (2009). The role of prefrontal cortex
CB1 receptors in the modulation of fear memory. Cereb. Cortex 19, 165–175. doi:
10.1093/cercor/bhn075
Lambert, J. J., Belelli, D., Peden, D. R., Vardy, A. W., and Peters, J. A. (2003).
Neurosteroid modulation of GABAA receptors. Prog. Neurobiol. 71, 67–80. doi:
10.1016/j.pneurobio.2003.09.001
Marshall, R. D., Beebe, K. L., Oldham, M., and Zaninelli, R. (2001). Efﬁcacy and
safety of paroxetine treatment for chronic PTSD: a ﬁxed-dose, placebo-controlled
study. Am. J. Psychiatry 158, 1982–1988. doi: 10.1176/appi.ajp.158.12.1982
Martijena, I. D., Rodríguez Manzanares, P. A., Lacerra, C., and Molina, V. A. (2002).
Gabaergic modulation of the stress response in frontal cortex and amygdala.
Synapse 45, 86–94. doi: 10.1002/syn.10085
Matsumoto, K., Uzunova, V., Pinna, G., Taki, K., Uzunov, D. P., Watanabe, H., et al.
(1999). Permissive role of brain allopregnanolone content in the regulation of
pentobarbital-induced righting reﬂex loss. Neuropharmacology 38, 955–963. doi:
10.1016/S0028-3908(99)00018-0
Myers, K. M., and Davis, M. (2007). Mechanisms of fear extinction. Mol. Psychiatry
12, 120–150. doi: 10.1038/sj.mp.4001939
Mihalek, R. M., Banerjee, P. K., Korpi, E. R., Quinlan, J. J., Firestone, L. L., Mi,
Z. P., et al. (1999). Attenuated sensitivity to neuroactive steroids in gamma-
aminobutyrate type A receptor delta subunit knockout mice. Proc. Natl. Acad.
Sci. U.S.A. 96, 12905–12910. doi: 10.1073/pnas.96.22.12905
Milad, M. R., Orr, S. P., Lasko, N. B., Chang, Y., Rauch, S. L., and Pitman,
R. K. (2008). Presence and acquired origin of reduced recall for fear extinc-
tion in PTSD: results of a twin study. J. Psychiatric Res. 42, 515–520. doi:
10.1016/j.jpsychires.2008.01.017
Mitchell, S. J., and Silver, R. A. (2003). Shunting inhibition modulates neuronal
gain during synaptic excitation. Neuron 38, 433–445. doi: 10.1016/S0896-
6273(03)00200-9
Mody, I., and Pearce, R. A. (2004). Diversity of inhibitory neurotrans-
mission through GABA(A) receptors. Trends Neurosci. 27, 569–575. doi:
10.1016/j.tins.2004.07.002
Mou, L., Heldt, S. A., and Ressler, K. J. (2011). Rapid brain-derived
neurotrophic factor-dependent sequestration of amygdala and hippocampal
GABA(A) receptors via different tyrosine receptor kinase B-mediated phospho-
rylation pathways. Neuroscience 176, 72–85. doi: 10.1016/j.neuroscience.2010.
12.041
Nelson, M., and Pinna, G. (2011). S-norﬂuoxetine microinfused into the
basolateral amygdala increases allopregnanolone levels and reduces aggres-
sion in socially isolated mice. Neuropharmacology 6, 1154–1159. doi:
10.1016/j.neuropharm.2010.10.011
Frontiers in Cellular Neuroscience www.frontiersin.org September 2014 | Volume 8 | Article 256 | 9
Pinna and Rasmusson Ganaxolone blocks contextual fear reconsolidation
Nin Schuler, M., Martinez, L. A., Thomas, R., Nelson, M., and Pinna, G. (2011).
Allopregnanolone and S-norﬂuoxetine decrease anxiety-like behavior in a mouse
model of anxiety/depression. Trab. Inst. Cajal 83, 215–216.
O’Sullivan, S. E. (2007). Cannabinoids go nuclear: evidence for activation of per-
oxisome proliferator-activated receptors. Br. J. Pharmacol. 152, 576–582. doi:
10.1038/sj.bjp.0707423
Panahi, Y., Moghaddam, B. R., Sahebkar, A., Nazari, M. A., Beiraghdar, F., Karami,
G., et al. (2011). A randomized, double-blind, placebo-controlled trial on the
efﬁcacy and tolerability of sertraline in Iranian veteranswith post-traumatic stress
disorder. Psychol. Med. 41, 2159–2166. doi: 10.1017/S0033291711000201
Papadopoulos, V., Baraldi, M., Guilarte, T. R., Knudsen, T. B., Lacapère, J. J., Lin-
demann, P., et al. (2006). Translocator protein (18 kDa): new nomenclature for
the peripheral-type benzodiazepine receptor based on its structure and molecular
function. Trends Pharmacol. Sci. 27, 402–409. doi: 10.1016/j.tips.2006.06.005
Pibiri, F., Nelson, M., Guidotti, A., Costa, E., and Pinna, G. (2008). Decreased
allopregnanolone content during social isolation enhances contextual fear: a
model relevant for posttraumatic stress disorder. Proc. Natl. Acad. Sci. U.S.A.
105, 5567–5572. doi: 10.1073/pnas.0801853105
Pinna, G. (2010). In a mouse model relevant for post-traumatic stress disorder,
selective brain steroidogenic stimulants (SBSS) improve behavioral deﬁcits by
normalizing allopregnanolone biosynthesis. Behav. Pharmacol. 21, 438–450. doi:
10.1097/FBP.0b013e32833d8ba0
Pinna, G. (2014). Targeting neurosteroidogenesis as therapy for PTSD. Front.
Pharmacol. 4:166. doi: 10.3389/fphar.2013.00166
Pinna, G., Agis-Balboa, R., Pibiri, F., Nelson, M., Guidotti, A., and Costa, E. (2008).
Neurosteroid biosynthesis regulates sexually dimorphic fear and aggressive behav-
ior in mice. Neurochem. Res. 33, 1990–2007. doi: 10.1007/s11064-008-9718-5
Pinna, G., Costa, E., and Guidotti, A. (2005). Changes in brain testosterone and
allopregnanolone biosynthesis elicit aggressive behavior. Proc. Natl. Acad. Sci.
U.S.A. 102, 2135–2140. doi: 10.1073/pnas.0409643102
Pinna, G., Costa, E., and Guidotti, A. (2006a). Fluoxetine and norﬂuoxetine stere-
ospeciﬁcally and selectively increase brain neurosteroid content at doses that
are inactive on 5-HT reuptake. Psychopharmacology (Berl.) 186, 362–372. doi:
10.1007/s00213-005-0213-2
Pinna, G., Agis-Balboa, R. C., Zhubi, A., Matsumoto, K., Grayson, D. R., Costa,
E., et al. (2006b). Imidazenil and diazepam increase locomotor activity in mice
exposed to protracted social isolation. Proc. Natl. Acad. Sci. U.S.A. 103, 4275–
4280. doi: 10.1073/pnas.0600329103
Pinna, G., Dong, E., Matsumoto, K., Costa, E., and Guidotti, A. (2003). In socially
isolated mice, the reversal of brain allopregnanolone down-regulation mediates
the anti-aggressive action of ﬂuoxetine. Proc. Natl. Acad. Sci. U.S.A. 100, 2035–
2040. doi: 10.1073/pnas.0337642100
Pinna, G., Galici, R., Schneider, H. H., Stephens, D. N., and Turski, L. (1997). Alpra-
zolam dependence prevented by substituting with the beta-carboline abecarnil.
Proc. Natl. Acad. Sci. U.S.A. 94, 2719–2723. doi: 10.1073/pnas.94.6.2719
Pinna,G., andRasmusson,A.M. (2012). Up-regulation of neurosteroid biosynthesis
as a pharmacological strategy to improve behavioural deﬁcits in a putative mouse
model of post-traumatic stress disorder. J. Neuroendocrinol. 24, 102–116. doi:
10.1111/j.1365-2826.2011.02234.x
Pistis, M., and Melis, M. (2010). From surface to nuclear receptors: the endo-
cannabinoid family extends its assets. Curr. Med. Chem. 17, 1450–1467. doi:
10.2174/092986710790980014
Puia, G., Santi, M. R., Vicini, S., Pritchett, D. B., Purdy, R. H., Paul, S. M., et al.
(1990). Neurosteroids act on recombinant human GABAA receptors. Neuron 4,
759–765. doi: 10.1016/0896-6273(90)90202-Q
Puia, G., Vicini, S., Seeburg, P. H., and Costa, E. (1991). Inﬂuence of recombi-
nant gamma-aminobutyric acid-A receptor subunit composition on the action
of allosteric modulators of gamma-aminobutyric acid-gated Cl- currents. Mol.
Pharmacol. 39, 691–696.
Qiu, Z. K., Zhang, L. M., Zhao, N., Chen, H. X., Zhang, Y. Z., Liu, Y. Q., et al.
(2013). Repeated administration of AC-5216, a ligand for the 18 kDa translo-
cator protein, improves behavioral deﬁcits in a mouse model of post-traumatic
stress disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 45, 40–46. doi:
10.1016/j.pnpbp.2013.04.010
Rademacher, D. J., Meier, S. E., Shi, L., Ho, W. S., Jarrahian, A., and Hillard,
C. J. (2008). Effects of acute and repeated restraint stress on endocannabinoid
content in the amygdala, ventral striatum, and medial prefrontal cortex in mice.
Neuropharmacology 54, 108–116. doi: 10.1016/j.neuropharm.2007.06.012
Rasmusson, A. M., Pinna, G., Paliwal, P., Weisman, D., and Gottshalk,
C. (2006). Decreased cerebrospinal ﬂuid allopregnanolone levels in women
with posttraumatic stress disorder. Biol. Psychiatry 60, 704–713. doi:
10.1016/j.biopsych.2006.03.026
Rasmusson, A. M., Schnurr, P., Zukowska, Z., Scioli, E., and Forman, D. E. (2010).
Adaptation to extreme stress: PTSD, NPY, and metabolic syndrome. Exp. Biol.
Med. 235, 1150–1156. doi: 10.1258/ebm.2010.009334
Rasmusson,A.M., and Shalev,A. (2014). “Integrating the neuroendocrinology, neu-
rochemistry, and neuroimmunology of PTSD to date and the challenges ahead”,
in Handbook of PTSD, 2nd Edn., eds M. Friedman, T. Keane, and P. Resick (New
York, NY: Guilford Publications Inc.), 166–189.
Reddy, D. S., and Rogawski, M. A. (2010). Ganaxolone suppression of behavioral
and electrographic seizures in the mouse amygdala kindling model. Epilepsy Res.
89, 254–260. doi: 10.1016/j.eplepsyres.2010.01.009
Rupprecht, R., Papadopoulos, V., Rammes, G., Baghai, T. C., Fan, J., Akula, N.,
et al. (2010). Translocator protein (18 kDa) (TSPO) as a therapeutic target for
neurological and psychiatric disorders. Nat. Rev. Drug Discov. 9, 971–988. doi:
10.1038/nrd3295
Rupprecht, R., Rammes, G., Eser, D., and Baghai, T. C. (2009). Translocator protein
(18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science
325, 490–493. doi: 10.1126/science.1175055
Sasso, O., La Rana, G., Vitiello, S., Russo, R., D’Agostino, G., and Iacono, A. (2010).
Palmitoylethanolamide modulates pentobarbital-evoked hypnotic effect in mice:
involvement of allopregnanolone biosynthesis. Eur. Neuropsychopharmacol. 20,
195–206 doi: 10.1016/j.euroneuro.2009.09.003
Sasso, O., Russo, R., Vitiello, S., Raso, G. M., D’Agostino, G., Iacono, A.,
et al. (2012). Implication of allopregnanolone in the antinociceptive effect of
N-palmitoylethanolamide in acute or persistent pain. Pain 153, 33–41. doi:
10.1016/j.pain.2011.08.010
Schüle, C., Eser, D., Baghai, T. C., Nothdurfter, C., Kessler, J. S., and
Rupprecht, R. (2011). Neuroactive steroids in affective disorders: target
for novel antidepressant or anxiolytic drugs? Neuroscience 191, 55–77. doi:
10.1016/j.neuroscience.2011.03.025
Schüle, C., Nothdurfter, C., and Rupprecht, R. (2014). The role of allo-
pregnanolone in depression and anxiety. Prog. Neurobiol. 113, 79–87. doi:
10.1016/j.pneurobio.2013.09.003
Scioli-Salter, E. R., Otis, J. D., Forman, D. E., Gregor, K., Valovski, I., and
Rasmusson, A. M. (2014). The shared neuroanatomy and neurobiology of
comorbid chronic pain & PTSD: therapeutic implications. Clin. J. Pain doi:
10.1097/AJP.0000000000000115 [Epub ahead of print].
Semyanov, A., Walker, M. C., and Kullmann, D. M. (2003). GABA uptake regulates
cortical excitability via cell type-speciﬁc tonic inhibition. Nat. Neurosci. 6, 484–
490. doi: 10.1038/nn1043
Semyanov, A., Walker, M. C., Kullmann, D. M., and Silver, R. A. (2004). Toni-
cally active GABAA receptors: modulating gain and maintaining the tone. Trends
Neurosci. 27, 262–269. doi: 10.1016/j.tins.2004.03.005
Slanina, K. A., and Schweitzer, P. (2005). Inhibition of cyclooxygenase-2 elicits
a CB1-mediated decrease of excitatory transmission in rat CA1 hippocampus.
Neuropharmacology 49, 653–659. doi: 10.1016/j.neuropharm.2005.04.019
Smith, S. S., Gong, Q. H., Li, X., Moran, M. H., Bitran, D., Frye, C. A., et al. (1998).
Withdrawal from 3alpha-OH-5alpha-pregnan-20-One using a pseudopregnancy
model alters the kinetics of hippocampal GABAA-gated current and increases the
GABAA receptor alpha4 subunit in association with increased anxiety. J. Neurosci.
18, 5275–5284.
Stern, C. A., Gazarini, L., Takahashi, R. N., Guimarães, F. S., and Bertoglio, L.
J. (2012). On disruption of fear memory by reconsolidation blockade: evi-
dence from cannabidiol treatment. Neuropsychopharmacology 37, 2132–2142.
doi: 10.1038/npp.2012.63
Sun, C., Sieghart,W., and Kapur, J. (2004). Distribution of alpha1, alpha4, gamma2,
and delta subunits of GABAA receptors in hippocampal granule cells. Brain Res.
1029, 207–216. doi: 10.1016/j.brainres.2004.09.056
Sundstrom-Poromaa, I., Smith, D. H., Gong, Q. H., Sabado, T. N., Li, X., Light, A.,
et al. (2002). Hormonally regulated alpha(4)beta(2)delta GABA(A) receptors are
a target for alcohol. Nat. Neurosci. 5, 721–722. doi: 10.1038/nn888
Suzuki, A., Mukawa, T., Tsukagoshi, A., Frankland, P. W., and Kida, S. (2008).
Activation of LVGCCs and CB1 receptors required for destabilization of reac-
tivated contextual fear memories. Learn. Mem. 15, 426–433. doi: 10.1101/
lm.888808
Frontiers in Cellular Neuroscience www.frontiersin.org September 2014 | Volume 8 | Article 256 | 10
Pinna and Rasmusson Ganaxolone blocks contextual fear reconsolidation
Tucker, P., Zaninelli, R., Yehuda, R., Ruggiero, L., Dillingham, K., and Pitts, C.
D. (2001). Paroxetine in the treatment of chronic posttraumatic stress disorder:
results of a placebo-controlled, ﬂexible-dosage trial. J. Clin. Psychiatry 62, 860–
868. doi: 10.4088/JCP.v62n1105
Umathe, S. N., Manna, S. S., and Jain, N. S. (2011). Involvement of endocannabi-
noids in antidepressant and anti-compulsive effect of ﬂuoxetine in mice. Behav.
Brain Res. 223, 125–134. doi: 10.1016/j.bbr.2011.04.031
Uz, T., Dimitrijevic, N., Akhisaroglu, M., Imbesi, M., Kurtuncu, M., and Manev,
H. (2004). The pineal gland and anxiogenic-like action of ﬂuoxetine in mice.
Neuroreport 15, 691–694. doi: 10.1097/00001756-200403220-00023
Uzunova, V., Sheline, Y., Davis, J. M., Rasmusson, A., Uzunov, D. P., Costa, E., et al.
(1998). Increase in the cerebrospinal ﬂuid content of neurosteroids in patients
with unipolar major depression who are receiving ﬂuoxetine or ﬂuvoxamine.
Proc. Natl. Acad. Sci. U.S.A. 95, 3239–3244. doi: 10.1073/pnas.95.6.3239
Vaiva, G., Thomas, P., Ducrocq, F., Fontaine, M., Boss, V., Devos, P., et al. (2004).
Low posttrauma GABA plasma levels as a predictive factor in the develop-
ment of acute posttraumatic stress disorder. Biol. Psychiatry 55, 250–254. doi:
10.1016/j.biopsych.2003.08.009
Vallée, M., Vitiello, S., Bellocchio, L., Hébert-Chatelain, E., Monlezun, S., Martin-
Garcia, E., et al. (2014). Pregnenolone can protect the brain from cannabis
intoxication. Science 343, 94–98. doi: 10.1126/science.1243985
Walderhaug, E., Kasserman, S., Aikins, D., Vojvoda, D., Nishimura, C., and
Neumeister, A. (2010). Effects of duloxetine in treatment-refractory men with
posttraumatic stress disorder. Pharmacopsychiatry 43, 45–49. doi: 10.1055/s-
0029-1237694
Westenberg, H. G. M. (1996). Development in the drug treatment of panic disorder:
what is the place of the selective serotonin reuptake inhibitors? J. Affect. Dis. 40,
85–93. doi: 10.1016/0165-0327(96)00043-2
Yu, H. L., Deng, X. Q., Li, Y. J., Li, Y. C., Quan, Z. S., and
Sun, X. Y. (2011). N-palmitoylethanolamide, an endocannabinoid exhibits
antidepressant effects in the forced swim test and the tail suspension
test in mice. Pharmacol. Rep. 63, 834–839. doi: 10.1016/S1734-1140(11)
70596-5
Zohar, J., Amital, D., Miodownik, C., Kotler, M., Bleich, A., Lane, R. M., et al. (2002).
Double-blind placebo-controlled pilot study of sertraline in military veterans
with posttraumatic stress disorder. J. Clin. Psychopharmacol. 22, 190–195. doi:
10.1097/00004714-200204000-00013
Conflict of Interest Statement: Marinus Pharmaceuticals provided ganaxolone to
the DOD sponsored INTRuST Veterans Administration multi-site study of ganax-
olone in PTSD, for which Christine Marx, MD, MA and Ann M. Rasmusson, MD
are Co-Lead Investigators.
Received: 11 June 2014; accepted: 11 August 2014; published online: 11 September
2014.
Citation: PinnaG and RasmussonAM (2014) Ganaxolone improves behavioral deﬁcits
in a mouse model of post-traumatic stress disorder. Front. Cell. Neurosci. 8:256. doi:
10.3389/fncel.2014.00256
This article was submitted to the journal Frontiers in Cellular Neuroscience.
Copyright © 2014 Pinna and Rasmusson. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Cellular Neuroscience www.frontiersin.org September 2014 | Volume 8 | Article 256 | 11
